DDIT3 and diffuse large B-cell lymphoma: Fostamatinib disodium, the first approved oral SYK inhibitor, was evaluated in a phase 1/2 trial (NCT00446095) of recurrent B-NHLs, showing an ORR of 22% in DLBCL, 10% in FL, and 11% in MCL.182 TAK-659 is being studied in a phase 2 trial in relapsed or refractory DLBCL (NCT03123393) alone, in combination with venetoclax in NHLs in a phase 1 trial (NCT03357627), and in combination with R-CHOP in DLBCL in a phase 1 trial (NCT03742258).